Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nelfinavir with Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma
NCT01555281Phase 2Terminated
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Feb 2012
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of nelfinavir in multiple myeloma (MM), sponsored by Swiss Group for Clinical Cancer Research. Primary endpoints: Dose Limiting Toxicity at 4 weeks and Overall Response at 16 weeks. Started Feb 2012; status: terminated.
02
Drugs
nelfinavir
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01555281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01555281.